Vireo Growth earnings release, May 12, 2026

Vireo Growth Inc. (VREOF) · Form 8-K, Item 2.02 · Filed · SEC filing

Vireo Growth Inc. Announces First Quarter 2026 Results

Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions

Moves to 4 th largest cannabis company on a pro forma basis by revenue

Closed the Schwazze acquisition and executed the PharmaCann MSA during the quarter

Closed the Eaze and Hawthorne acquisitions subsequent to quarter end

Announced a definitive agreement to acquire FLUENT and a joint venture with Glass House Brands subsequent to quarter end

Company closed Q1 with $137.8 million in cash; expects to remain acquisitive

MINNEAPOLIS – May 12, 2026 – Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2026. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.

Year-over-Year Performance Summary

​¹

Non-GAAP measure. Excludes fair value adjustments and non-cash product costs.²

Non-GAAP measure. See

Supplemental Information and Reconciliation of Non-GAAP Financial Measures.³

Pro forma results give effect to the acquisitions of Deep Roots, Proper, Wholesome, Schwazze, Eaze, PharmaCann, and Hawthorne (the “Acquisitions”) as if they were completed on January 1, 2025. Pro forma information has been presented for informational purposes only and is not necessarily indicative of the Company’s past results of operations, nor is it indicative of the future operating results of the Company and should not be considered a substitute for the financial information presented in accordance with GAAP.

​

Sequential Performance Summary¹

Non-GAAP measure. Excludes fair value adjustments and non-cash product costs.²

Non-GAAP measure. See

Supplemental Information and Reconciliation of Non-GAAP Financial Measures.

​

Management Commentary

Chief Executive Officer John Mazarakis commented, “First quarter performance remained in line with our expectations and we are excited to welcome Schwazze, Eaze, and Hawthorne to Vireo. We are focused on integration and optimization across the platform while remaining opportunistic with respect to further acquisition related growth opportunities.”

Recent Developments

On March 19, 2026, the Company completed its previously announced acquisition of a controlling interest in Vireo Health of Rocky Mountain, LLC through the restructuring of Medicine Man Technologies Inc. (dba Schwazze). In connection with the transaction, the Company acquired 45 dispensaries and two manufacturing facilities located in Colorado and New Mexico.

​

On March 22, 2026, the management services agreement previously entered into in connection with the Company’s pending acquisition of certain PharmaCann Inc. assets became effective, pursuant to which the Company began providing management services related to the dispensaries to be acquired.

​

On April 1, 2026, the Company completed its previously announced merger with Eaze, Inc. (“Eaze”), with Eaze becoming a wholly owned subsidiary of the Company. In connection with the closing, the Company issued 90,379,591 subordinate voting shares as estimated closing consideration, a portion of which was placed in escrow, subject to customary post-closing adjustments. Former Eaze stockholders may also be eligible to receive additional shares based on the achievement of certain financial targets through December 31, 2026.

​

On April 8, 2026, the Company completed the acquisition of The Hawthorne Gardening Company LLC and its subsidiaries from The Scotts Miracle-Gro Company. In connection with the transaction, the Company issued 213,000,000 subordinate voting shares, a portion of which was placed in escrow, subject to customary post-closing adjustments. The Company also issued warrants to purchase 80,000,000 subordinate voting shares at an exercise price of $0.85 per share with a five-year term.

​

On April 13, 2026, the Company and Glass House Brands Inc. (“Glass House”) announced the execution of a definitive agreement to form a joint venture to combine each party’s California dispensary operations, subject to the satisfaction of regulatory approvals and other customary closing conditions. Upon closing, each party is expected to contribute its respective California retail operations to the joint venture in exchange for a 50% ownership interest. The joint venture agreement contemplates combining the Company’s twelve dispensaries and home delivery operations located in California and acquired from Eaze with Glass House’s eleven California retail locations. The combined retail platform is expected to be supported by a preferential supply agreement with Glass House. Under the terms of the agreement, beginning five years after closing, the Company will have an option to acquire Glass House’s ownership interest in the joint venture, and Glass House will have a reciprocal put right.

​

On April 23, 2026, the U.S. Department of Justice announced an order reclassifying certain FDA-approved marijuana products and cannabis products subject to qualifying state medical marijuana licenses from Schedule I to Schedule III under the Controlled Substances Act. The Department of Justice also announced an administrative hearing process to consider broader rescheduling of marijuana. The Company is currently evaluating the potential impact of these developments on its operations, tax position, and financial statements.

​... (truncated)ors abstaining from voting) following a review by an independent special committee of FLUENT and is subject to customary conditions, including FLUENT shareholder approval, court and regulatory approvals, as well as the completion of a debt equitization of approximately $30 million of FLUENT indebtedness. The agreement also contains certain covenants and agreements regarding the conduct of FLUENT’s business until the closing, including covenants requiring FLUENT and its subsidiaries to manage and operate their respective businesses in accordance with an operating budget that was approved by FLUENT’s board of directors and adopted by FLUENT in connection with the transaction.

​

Balance Sheet and Liquidity

As of March 31, 2026, total current assets excluding assets held for sale and income taxes receivable were $239.7 million, including cash on hand of $137.8 million. Total current liabilities excluding uncertain tax liabilities were $82.0 million. As of March 31, 2026, the Company had a total of 1,173,995,207 subordinate voting shares outstanding on the treasury method basis using a share price of $0.50. As of May 12, 2026, the Company had 1,568,115,539 subordinate voting shares outstanding on a treasury method basis using a share price of $0.50.

Conference Call and Webcast Information

Vireo management will host a conference call with research analysts today, May 12, 2026, at 8:00 a.m. ET (7:00 a.m. CT) to discuss its financial results for its first quarter ended March 31, 2026. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 1197610.

A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website and via the following link: https://events.q4inc.com/attendee/568347124.

About Vireo Growth Inc.

Vireo was founded in 2014 as a pioneering medical cannabis company. Vireo is building a disciplined, strategically aligned, and execution-focused platform in the industry. This strategy drives our intense local market focus while leveraging the strength of a national portfolio. We are committed to hiring industry leaders and deploying capital and talent where we believe it will drive the most value. Vireo operates with a long-term mindset, a bias for action, and an unapologetic commitment to its customers, employees, shareholders, industry collaborators, and the communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Additional Information

Additional information relating to the Company’s first quarter 2026 results will be available on EDGAR and SEDAR+ later today. Vireo refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, and Adjusted Gross Profit Margin in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures including a reconciliation of each measure to the most directly comparable GAAP financial measure.

Contact Information

Joe Duxbury

Chief Accounting Officer investor@vireogrowth.com

(612) 314-8995

Forward-Looking Statement Disclosure

Financial statements

Income Statement

Three Months Ended — Year-over-Year Performance Summary (in millions)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Three Months Ended – March 31, – Variance
GAAP Revenue106.224.5333.5%
GAAP Gross Profit59.312.4378.2%
Gross Profit Margin55.8%50.6%520 bps
Adjusted Gross Profit(1)59.813.1356.5%
Adjusted Gross Profit Margin(1)56.3%53.5%280 bps
Adjusted EBITDA (non-GAAP)(2)32.76.6395.5%
Adjusted EBITDA Margin(2)30.8%26.9%390 bps

Income Statement

Three Months Ended — Sequential Performance Summary (in millions)

Three Months Ended – March 31, 2026Three Months Ended – December 31, 2025Three Months Ended – Variance
GAAP Revenue106.2104.51.6%
GAAP Gross Profit59.356.94.2%
Gross Profit Margin55.8%54.4%140 bps
Adjusted Gross Profit(1)59.858.81.7%
Adjusted Gross Profit Margin(1)56.3%56.3%0 bps
Adjusted EBITDA (non-GAAP)(2)32.729.510.8%
Adjusted EBITDA Margin(2)30.8%28.2%260 bps

Income Statement

Three Months Ended — (Amounts Expressed in millions of United States Dollars, Unaudited)

Three Months Ended – March 31, – 2026 (pro forma)1Three Months Ended – March 31, – 2025 (pro forma)1$ Change% Change
Retail:MN18.211.2763.0%
Retail:NY0.81.2-0.4-33.0%
Retail:MD6.66.8-0.2-3.0%
Retail:UT12.311.21.110.0%
Retail:NV27.423.53.917.0%
Retail:MO20.718.32.413.0%
Retail:CO & NM54.261.9-7.7-12.0%
Retail:CA17.819.4-1.6-8.0%
Retail:FL8.94.74.289.0%
Retail:Total Retail166.9158.28.75.5%
Wholesale:MN$—0.3-0.3-100.0%
Wholesale:NY5.20.94.3478.0%
Wholesale:MD3.44.1-0.7-17.0%
Wholesale:UT2.820.840.0%
Wholesale:NV0.20.2
Wholesale:MO4.73.11.652.0%
Wholesale:CO & NM0.50.40.125.0%
Wholesale:Total Wholesale16.8115.853.0%
Wholesale:Total Cannabis Revenue183.7169.214.59.0%
Wholesale:Non-Cannabis Revenue26.530.9-4.4-14.0%
Wholesale:Total Revenue210.2200.110.15.0%

Income Statement

Three Months Ended

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025Three Months Ended – March 31, – 2026 (pro-forma)1Three Months Ended – March 31, – 2025 (pro-forma)1
Net income (loss)-20.3-6.5-28.1-9.9
Interest expense, net7.87.614.718.1
Income taxes16.11.716.17.1
Depreciation & Amortization3.80.29.88.7
Depreciation and amortization included in cost of sales2.90.62.90.6
EBITDA (non-GAAP)10.33.615.424.6
Non-cash inventory adjustments0.50.40.50.4
Grown Rogue termination fee included in cost of goods sold0.30.3
Change in the fair value of contingent consideration5.55.5
Stock-based compensation71.571.5
Transaction related expenses8.71.2103.5
Other (income) expense0.7-0.81-0.7
Severance expense0.40.20.6
Loss on disposal of assets0.50.1
Adjusted EBITDA (non-GAAP)32.76.640.130.3

Income Statement

Three Months Ended

Three Months Ended – March 31, – 2026 (pro-forma)1Three Months Ended – March 31, – 2025 (pro-forma)1
Net income (loss)1.10.6
Depreciation & Amortization0.50.9
Depreciation and amortization included in cost of sales0.10.1
EBITDA (non-GAAP)1.71.6
Stock-based compensation0.40.6
Adjusted EBITDA (non-GAAP)2.12.2

Income Statement

(Amounts Expressed in millions of United States Dollars, Unaudited and Condensed)

Unaudited Three Months Ended March 31, – 2026Unaudited Three Months Ended March 31, – 2025
Revenue106.224.5
Cost of salesProduct costs46.411.7
Cost of salesNon-cash product costs0.2
Cost of salesInventory valuation adjustments0.30.4
Cost of salesGross profit59.312.4
Operating expenses:Selling, general and administrative expenses30.87.4
Operating expenses:Transaction related expenses8.71.2
Operating expenses:Stock-based compensation expenses71.5
Operating expenses:Depreciation1.10.1
Operating expenses:Amortization2.70.2
Operating expenses:Total operating expenses50.310.4
Operating expenses:Income (loss) from operations92
Other income (expense):Interest expenses, net-4.2-4
Other income (expense):Interest expense on finance lease liabilities - Minnesota & New York-3.6-3.6
Other income (expense):Gain (loss) on change in the fair value of contingent consideration-5.5
Other income (expense):Derivative gain (loss)0.1
Other income (expense):Other income (expenses)0.8
Other income (expense):Other income (expenses), net-13.2-6.8
Other income (expense):Loss before income taxes-4.2-4.8
Other income (expense):Deferred income tax recoveries (expenses)2.2
Other income (expense):Current income tax expenses-18.3-1.7
Other income (expense):Net loss and comprehensive loss-20.3-6.5
Other income (expense):Net loss per share - basic and diluted-0.02-0.02
Other income (expense):Weighted average shares used in computation of net loss per share - basic and diluted1,080,450,771366,800,177

Balance Sheet

December 31, — (Amounts Expressed in millions of United States Dollars, Unaudited and Condensed)

March 31, – 2026December 31, – 2025
Current assets:Cash122.4102.2
Current assets:Restricted cash15.420.3
Current assets:Marketable securities11
Current assets:Accounts receivable, net of credit losses of $1.8 million and $1.3 million, respectively16.113.8

Cash Flow

Three Months Ended March 31, — (Amounts Expressed in millions of United States Dollars, Unaudited and Condensed)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet loss-20.3-6.5
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash amortization of inventory step up included in product costs0.2
Adjustments to reconcile net loss to net cash used in operating activities:Inventory valuation adjustments0.30.4
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation1.10.1
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation capitalized into inventory2.90.5
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash operating lease expense1.10.1
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of intangible assets2.70.2
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation71.3
Adjustments to reconcile net loss to net cash used in operating activities:Warrants held0.80.5
Adjustments to reconcile net loss to net cash used in operating activities:Derivative (gain) loss-0.1
Adjustments to reconcile net loss to net cash used in operating activities:Interest Expense1.11.2
Adjustments to reconcile net loss to net cash used in operating activities:Bad debt expense0.1
Adjustments to reconcile net loss to net cash used in operating activities:Accretion of interest on right-of-use finance lease liabilities0.1
Adjustments to reconcile net loss to net cash used in operating activities:(Gain) loss on change in the fair value of contingent consideration5.5
Change in operating assets and liabilities:Accounts Receivable-1.10.6
Change in operating assets and liabilities:Prepaid expenses-2-0.1
Change in operating assets and liabilities:Inventory-2.2-2
Change in operating assets and liabilities:Income taxes4.50.7
Change in operating assets and liabilities:Deferred income tax expense (benefit)-2.2
Change in operating assets and liabilities:Uncertain tax position liabilities13.81.6
Change in operating assets and liabilities:Accounts payable and accrued liabilities1.8
Change in operating assets and liabilities:Changes in operating lease liabilities-1.3-0.4
Change in operating assets and liabilities:Change in assets and liabilities held for sale-3.5
Change in operating assets and liabilities:Net cash provided by (used in) operating activities11.9-3.4
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property, plant, and equipment-10.8-1.1
CASH FLOWS FROM INVESTING ACTIVITIES:Acquisition of Schwazze, net of cash received18.2
CASH FLOWS FROM INVESTING ACTIVITIES:Capitalized software development costs-0.5
CASH FLOWS FROM INVESTING ACTIVITIES:Deposits1.1
CASH FLOWS FROM INVESTING ACTIVITIES:Net cash provided by (used in) investing activities8-1.1
CASH FLOWS FROM FINANCING ACTIVITIESDebt principal payments-4.5-0.9
CASH FLOWS FROM FINANCING ACTIVITIESLease principal payments-0.1
CASH FLOWS FROM FINANCING ACTIVITIESNet cash provided by (used in) financing activities-4.6-0.9
CASH FLOWS FROM FINANCING ACTIVITIESNet change in cash15.3-5.4
CASH FLOWS FROM FINANCING ACTIVITIESCash and restricted cash, beginning of period122.591.6
CASH FLOWS FROM FINANCING ACTIVITIESCash and restricted cash, end of period137.886.2
Full release

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the Company’s future M&A strategy and optimization of the Company’s business; the Company’s expectations around its pending transactions with PharmaCann and FLUENT and the assets to be acquired therefrom; and expectations around the joint venture involving Glass House and the consummation of the related contributions of California dispensary operations by Vireo and Glass House. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue, EBITDA, Adjusted EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to risks related to receipt of necessary regulatory and third-party approvals for completion of the Company’s pending and proposed transactions; risks and uncertainties associated with the pending transactions with PharmaCann and FLUENT and the joint venture with Glass House, some of which are beyond the Company’s control; the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties as a result of the pending transactions with PharmaCann and FLUENT and the joint venture with Glass House; the effects of the pending transactions with PharmaCann and FLUENT and the joint venture with Glass House on the Company and the interests of various constituents; subject to the successful outcome of the pending transactions with PharmaCann and FLUENT and the proposed contributions of California dispensary operations to the Glass House joint venture, the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; the Company’s ability to dispose of its assets held for sale at an acceptable price or at all; and risk factors set out in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

VIREO GROWTH INC.

STATE-BY-STATE REVENUE PERFORMANCE

THREE MONTHS ENDED MARCH 31, 2026, 2025, 2026 PRO FORMA, AND 2025 PRO FORMA

(Amounts Expressed in millions of United States Dollars, Unaudited)

​¹

Pro forma results give effect to the Acquisitions as if they were completed on January 1, 2025. Pro forma information has been presented for informational purposes only and is not necessarily indicative of the Company’s past results of operations, nor is it indicative of the future operating results of the Company and should not be considered a substitute for the financial information presented in accordance with GAAP.

​

​

​

​

Supplemental Information and Reconciliation of Non-GAAP Financial Measures

Vireo management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, and Adjusted Gross Profit Margin. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, and Adjusted Gross Profit Margin are non-GAAP measures and do not have standardized definitions under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

Reconciliation of Net Loss to EBITDA and Adjusted EBITDA... (truncated)abis and non-cannabis operations on a pro forma basis.

​¹

Pro forma results give effect to the acquisitions of Deep Roots, Proper, Wholesome, Schwazze, Eaze, PharmaCann, and Hawthorne (the “Acquisitions”) as if they were completed on January 1, 2025. Pro forma information has been presented for informational purposes only and is not necessarily indicative of the Company’s past results of operations, nor is it indicative of the future operating results of the Company and should not be considered a substitute for the financial information presented in accordance with GAAP.

​

The financial information reported in this news release is based on the Company’s unaudited financial statements for the three months ended March 31, 2026, and 2025. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s unaudited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s unaudited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Vireo Growth earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.